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( 57 } ABSTRACT
The present invention provides systems Ibr growing two or
three dimensional mammalian cells within a culture tnediunl
facilitated by' an electromagnetic field, and preferably, a time
varying electromagnetic field. The cells and culture medium
are contained within a fixed or rotating culture vessel, and
the electromagnetic field is enfitted from at least one elec-
trode. In one embodiment, the electrode is spaced from the
vessel. The invention further provides methods to promote
neural tissue regeneration by means of culturing the neural
cells in the claimed system. In one embodiment, neuronal
cells are grown within longitudinally extending tissue
strands extending axially along and within electrodes con>
prising electrically conductive channels or guides through
which a time vwying electrical current is conducted, the
conductive channels being positioned within a culture
medium,
18 Claims, 11 Drawing Sheets
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GROWTH STIMULATION OF BIOLOGICAL
CELLS AND TISSUE BY
ELECTROI_L_XGNETIC FIELDS AND USES
THEREOF
5
ORIGIN OF THE INVENTION
The invention described herein was made by an employee
of the United States Government and may be manufactured
and used by or for the Government of the United States of
America for governmental purposes without the payment of t0
any royalties thereon or therefor.
BACKGROUND OF THE INVENTION
1. Field of the Invention 15
The present invention relates generally to the fields of
biophysics, tissue regeneration, tissue culture, and neurobi-
ology. More specifically, the present invention relates to the
use of an electromagnetic field, and preferably, a time
varying electromagnetic field, for potentiation of or control- 2o
ling the growth of biological cells and tissue, such as
mammalian tissue. More specifically, the present invention
relates to the use of an electromagnetic field for controlling
the growth of neural cells and tissues. The preferred embodi-
ment utilizes two-dimensional conducting plate electrodes 25
and may be applied to conventional, two dimensional tissue
cultures or to three-dimensional cultures. Three dimensional
cultures may be achieved in actual microgravity or by
rotating wall vessel technology which simulates the physical
conditions of microgravity, and in other, conventional three- 3o
dimensional matri:_ based cultures. The electromagnetic
field, preferably a time varying electromagnetic field, is
achieved in tile vicinity of the electrode by passing, through
the electrode, a time varying current.
2. Description of the Related Art 35
Growth of a variety of both normal and neoplastic mam-
malian tissues in both mono-culture and co-culture has been
established in both batch-ted and perfused rotating wall
vessels (1-2), and in conventional plate or flask based
culture systems. In some applications, growth of three- 40
dimensional structure, e.g., tissues, in these culture systems
has been facilitated by support of a solid matrix in the form
of biocompatible polymers and microcarriers. In the case of
spheroidal _owth, three-dimensional structure has been
achieved without matrix support _,_-_i. NASA rotating wall as
tissue culture technologies have extended this three dimen-
sional capacity for a number of tissues and has allowed the
tissue to express different genes and biomolecules. Neuronal
tissue has been largely refractory, in terms of controlled
growth induction and three dimensional organization, under 5o
conventional culture conditions. Actual microgravit 5. and to
it lesser extent, rotat onally simulated microgravity, have
permitted some enhanced nerve growth (Lelkes et al).
Attempts to electrically stimulate growth have utilized static
electric fields, static magnetic fields, and the direct passage 55
of current through the culture medium, though not the
induction of a time var),ing electromagnetic field in the
culture region.
Neuronal tissue comprises elongated nerve cells com-
posed of elongated axons, dendrites, and nuclear areas, o0
Axons and dendrites are chiefly responsible for transmission
of neural signals over distance and longitudinal cell orien-
tation is critical for proper tissue formation and function.
The nucleus plays the typical role of directing nucleic acid
synthesis for the control of cellular metabolic function. 65
including growth, in vivo, the neuronal tissue is invariably
spatially associated with a system of feeder, or glial, cells.
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This three dimensional spatial arrangement has not been
reproduced by conventional in vitro culture. Investigators.
Borgens RB et al. and others, have utilized static electric
fields in an attempt to enhance nerve growth in culture.
_Valentini el al) with some success to either alter embryonic
development or achieve isolated nerve axon directional
growth. However, actual potentiation of _owth or genetic
activity causing such. have not been achieved. Mechanical
devices intended to help grow and orient three dimensional
mammalian neuronal tissue are currently available. Fukuda
el al. (7) used zones formed between stainless steel shaving
blades to orient neuronal cells or axons. Additionally. elec-
trodes charged with electrical potential were employed to
enhance axon response. Aebischer _81 described an
electrically-charged, implantable tubular membrane for use
in regenerating severed nerves within the human body.
However, none of these devices utilize channels of cell-
attractive material, neither do they apply a time varying
electromagnetic field, or a static electrical or magnetic field.
Additionally, no use is made of simulated or actual micro-
gravity techniques for pure neuronal, or mixed, neuronal and
feeder cell cultures. The prior art is deficient in its lack of
effective means for growing three dimensional mammalian
neuronal tissue in the proximity of, or directly upon the
surface, of a current carrying electrode (which may be
bioattractive and directly adherent to the cells). Furthernaore.
the use of a time varying current to induce a corresponding
time varying electromagnetic field, in the vicinity of tile
growing culture, to potentiate or spatially direct cell gowth
is not part of the prior art.
SUMMARY OF THE INVENTION
The present invention relates to a system and method for
culturing biological cells, such as mammalian cells, within
a culture medium. The cells are exposed to an electromag-
netic field, which, in the preferred embodiment, is a time-
varying electromagnetic field. In the preferred embodiment,
this field is generated by a conductive electrode, adjacently
spaced from the incubating cells, carrying a time varying
electrical current. The electrode, in one case, is in direct
galvanic contact with the culture media and cells, and in
another case, it is placed external to the culture apparatus in
a galvanicall.v isolated condition. Preferably. a 10 hertz
square wave of 1-6 milliamperes, and with nearly zero time
average, is passed through the electrode, suitably from
corner to opposite comer of a square metallic conductive
plate. The cells, such as neurons in this case, were, in one
embodiment, grown directly on the electrode surface, com-
posed of a biocompatable material. In another embodiment,
the cells were grown within a container under the influence
of a time varying electromagnetic field from an electrode
external of and adjacent to the container, galvanically iso-
lated from the media and culture within the container.
The growing cells may actually be attracted and trophi-
cally supported by more supportive electrode material or
coatings. Furthermore, channels may be incorporated in the
culture vessel and lined with growth substrate which may be
electrically conductive. In one embodiment, a time varying
electromagnetic field is induced in the region of the channel
by passing the time varying current through a conductor
placed along the channel. This arrangement will further
direct growth by the combined effect of the field and trophic
materials.
In the preferred embodiment, the presence of the time
varying electromagnetic field potentiates the growth of
nerve and other tissue. The time varying field may be
induced by either: [) a time varying current within a
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conductor, or 2) a time varying voltage between fixed
conductors. In one embodiment, lbr example, the culture is
placed nearby a conductor through which a time varying
current is passed, or between parallel plates upon which a
time varying voltage is applied. In both cases, a time varying
electromagnetic field results within the area of interest, i.e.,
in the region of the cell culture.
The system and process are utilized in combination with
known tissue culture processes to produce enhanced cell
growth, directed cell growth, and tissue formation and
organization.
As will be understood from the description to follo,,v, the
system is operable to up or down regulate the activity of
specific genes. In general, growth promoting genes are up
regulated and growth inhibitory genes are down regulated.
The effect is shown to persist for some period after termi-
nation of the applied time varying field. This persistent,
growth promoting effect subsides after a period of some
days, and the cells return to a growth state characterized by
controls, having never been exposed to the fields. This is
beneficial in certain applications, in that medical applica-
tions for clinical medical care. i.e. nerve regeneration, are
therefore safer than if the "'pseudo transformed" state per-
sisled. The set of gene transformations, associated with the
time varying electromagnetic field, also promote the ability
of the _owing tissue to adhere and thrive on substrates by
the induction of genes leading to the secretion of extracel-
lular materials favorable to the tissue microenvironment.
Several methods of producing the time varying electro-
magnetic field in the vicinity of the living tissue culture are
encompassed. In one embodiment, an array of conductive
current carrying elements Ior voltaic etectrodes_ are
,arranged so as to intensif', or focus the time varying elec-
tromagnetic IEMI field onto the culture. Each embodiment
is characterized by a method for application of the time
varying field to the target tissue, such as neuronal, for
stimulation of growth, or repair or induction of changes in
gene activity patterns. The term "'field generator" is used
herein to represent these various embodiments for generat-
ing the time varying electromagnetic fields. In its simplest
form, it is a conductive electrode, placed near the target
cells, through which current is directed from a controlled
waveform current source.
As suggested above, in one embodiment, the field gen-
erator is in the forn_ of a conductive channel mounted on or
embedded in a disc of biocompatable material. (FIG. 11)
One or more of these discs may be then placed within a
rotational bioreactor so as to obtain the beneficial culture
conditions associated therewith. The combination of the
stimulatory electromagnetic field with the rotational
environment, known to pernfit morphological expression
beyond conventional culture, is particularly effective. This is
because the induced pattern of growth enhancing genes is
permitted to be ultimately expressed, as cell _owth and
tissue formation, without mechanical inhibition from the
culture apparatus. Also the inherent growth advantages well
known in the rotational systems is synergistic with the
grov,,th stimulation derived from the time varying electro-
magnetic field. The conditions may be further optimized by
utilizing actual microgravity, in space. In this application,
mechanical rotation of the cell culture vessel is not required
but may be utilized to achieve mixing and sufficient mass
transfer to sustain a healthy culture. Other forms of mixing
may be introduced as necessary to achieve adequate mass
transfer for each embodiment.
In one embodiment, illustrated in FIGS. 10 and 11,
slip-ring contacts or their equivalents are electrically con-
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nected to the ends of the channels, and an external power
source is provided for applying the time vary, ing electrical
current defining the waveforna ttu-ough the channels. In
another embodiment, the channel consists of a pair of
5 parallel, mutuall._ spaced conductors across which a time
varying voltage is applied. Tiffs also achieves the time
varying electromagnetic field hut restricts it to the region
between the parallel electrodes, which is advantageous for
directing localized growth according to a desired physical
IO pattern. The present invention also relates to a system and
method for culturing primarily two dimensional mammalian
cells facilitated b 3 a time varying electromagnetic field. The
electrodes may either be in direct galvanic contact or gal-
vanically isolated from the target cells. The present inven-
tion provides a strategy to re-engineer nerve tissue and15
myoneural junctions and can be used medically for axonal
regeneration.
tn one embodiment of the present invention, there is
provided a system for growing three dimensional mamma-
20 lian cells, comprising a rotating wall vessel containing a
cell-rich medium and a fornaed cell growth substrate. A time
varying electromagnetic field is applied to enhance tissue
growth which may occur on a shaped substrate. The elec-
tromagnetic field may be generated by means such as by
25 directing the current waveforn_ directly through a conduc-
tive substrate tor substrate layer) or by projecting the field
from an external antenna, or electrode adjacent to and
spaced from the medium, the spacing being sufficientl3
small relative to the strength or the electromagnetic field to
3o induce effectual levels of electromagnetic field within the
medium, in accordance with the particular application. A
time varying electromagnetic field may be emitted from a
nearby plate or other suitable "'antennae," or a time varying
voltage may be applied across suitable electrodes (such as
35 plates_ to produce the time varying electromagnetic field.
The field generation system may either be rotating with the
vessel or fixed, and spaced from, the rotating vessel. The
rotating wall vessel can be a rotating wall peffused vessel or
a rotating wall batch-fed vessel.
4o The time varying electromagnetic field is advantageously
produced by a varying electrical potential in the form of a
square wave having a frequency of approximately ten cycles
per second. In one embodiment, a current of about ten
milliamps, conducted between opposite comers of a metallic
45 conductor, produces a stimulatory time varying electromag-
netic field extending several centimeters from the plate
surface. In practice, the range of frequency and oscillating
electromagnetic field strength is a parameter which may be
selected to for achieving the desired stimulation of particular
5o tissues, cells, or genes, and for providing the appropriate
amount of up/down regulation of these genes.
In one embodiment of the present invention, the cell
growth susbtrates or carriers are spherical disks containing
multiple parallel channels (FIG. 10! which are coated with
55 a bioattractive material. The bioattractive material has a
longitudinal axis across which the time varying electrical
potential is applied and through which a time varying
current is conducted. The mammalian cells adhere to the
bioattractive material and are free to orient, as the)' grow.
6o Representative bioattractive materials include titanium, zir-
conium and platinum.
The class of mammalian cells preferably is selected from
the group consisting of neuronal cells, normal human neu-
ronal progenitor cells _NHNPI, and a cell responding to the
65 time varying electromagnetic field. It will be understood bv
those of ordinary skill in the art that the teachings of the
present invention apply to other cell types.
US 6,485,963 B I
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In another embodiment of the present invention, there is
provided a method of culturing mammalian cells in the
claimed system, comprising the steps of inoculating the cells
into the vessel containing a culture medium, rotating the
vessel to enhance the proliferation of the cells and, in one
embodiment, to initiate the attachment of the cells to micro-
carrier spheres or beads suspended within the culture
medium, applying a time varying electromagnetic field to
the culture medium, cells, and cell carriers, and measuring
the growth of the cells. Preferably. the vessel is rotated at a
speed from ,'lbout 2 RPM to 30 RPM, and the time varying
electromagnetic field is generated by a time varying current
passed through a conductor with RMS value of about I to
1,0(X) ma. In one embodiment, a range of about I mA to 6
mA is used.
In still another embodiment of the present invention, there
is provided a system for growing two-dimensional neural
cells, comprising a petri dish containing a cell culture
medium and an electrode placed in the center of the petri
dish. In this embodiment, the electrode serves as the field
generator. Preferably, the neural cells are applied directly on
the electrode. As a result, the neutral cells exhibit acceler-
ated growth.
In vet another embodiment of the present invention, there
is provided a system for growing two-dimensional neural
cells further comprising a slide placed on the electrode.
Preferably, the neural ceils are applied, e.g., bubbled, on the
slide instead of directly contacting the electrode, and
preferably, the current producing the waveform is applied at
a strength range of from about I mA to about 100 mA, and,
in one embodiment, suitably from about I mA to 6 mA.
In still another embodiment of the present invention, there
is provided a method of treating an individual having
diseased neuronal cells, comprising the steps of _owing
neuronal cells in the claimed two- or three- dimensional
systems and transplanting the neuronal cells into the indi-
vidual. Such diseases include Parkinson's disease, diseases
of neuromuscular junction and Alzheimer's Disease. Neural
trauma can also be treated in same methodology,.
In yet another embodiment of the present invention, the
time varying electromagnetic field _or electrical potential)
induces cellular response including cellular control of
_owth and differentiation at gene level. Preferably, the
cellular control of growth and differentiation is to suppress
or enhance growth regulatory functions at gene level. Still
preferably, the gene is associated with increased tissue and
cell proliferation.
Other and further aspects, features, and advantages of the
present invention will be apparent from the following
description of the presently preferred embodiments of the
invention given for the purpose of disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features,
advantages and objects of the invention, as well as others
which will become clear, are attained and can be understood
in detail, more particular descriptions of the invention
brieflv summarized above may be had by' reference to
certain embodiments thereof which are illustrated in the
appended drawings. These drawings form a part of the
specification. It is to be noted, however, that the appended
drawings illustrate preferred embodiments of the invention
and therefore are not to be considered limiting in their scope.
FIG. 1 shows a petri dish with cells in a concentrated
bubble placed on the metal electrode in the center of the
dish.
6
FIG. 2 shows normal human neuronal progenitor _NHNP_
cells grown in conventional tissue culture procedures.
FIG. 3 shows the perimeter of non-waveform influenced
normal human neuronal progenitor cells 24 hours after the
5 experinaent.
FIG. 4 shows neural tube formation within nornal human
neuronal progenitor cells under the influence of waveform.
FIG. 5 shows neural tube generation within normal
human neuronal progenitor cells under the influence of10
waveform.
FIG. 6 shows the composition of waveform-influenced
neural tissue 24 hours after the exposure.
FIG. 7 shows the waveform-influenced normal human
15 neuronal progenitor cells 24 hours after the exposure.
FIG. 8 shows a close-up of waveform-influenced normal
human neuronal progenitor cells.
FIG. 9 shows waveform-influenced normal human neu-
ronal progenitor cells 24 hours after the exposure.
20
FIG. 10 shows prototype of the system 1, consisting of
silicon plates 2, fluid coupling 3, slip rings 4. a rotating wall
pressure vessel (RWPVI 5. electrical conductor 6 d.e., an
electrical conductive bioattractive inlay' strip), a perfusion
inlet 7, perfusion outlet 8, a stand for the rotating wall25
pressure vessel 9 and a source of time varying electrical
current 10.
FIG. IIA is a plan view of one of the disc-shaped silicon
plates 2, showing a central opening 11 about which rotation
3o occurs, the electrical conductors 6, and electrical contacts 12
connected to the strips at opposite ends thereof. FIG. liB is
a side view of the silicon plate 2, demonstrating the elec-
trical contacts 12 and the electrical conductive strips, in the
form of bioattractive inlays 6.
35 DETAILED DESCRIPTION OF THE
INVENTION
As used herein, the term "bioattractive material" shall
refer to materials to which a cellular material will attach.
40 As used herein, the term "'longitudinally' orient" shall refer
to orientation in an elongated cordlike fashion.
As used herein, the term "parallel channels" shall refer to
electric channels which are designed to provide constant
output to all the electrodes simultaneously.
45 As used herein, the term "'cell carriers" shall refer to
microcarrier beads, scaffolds and matrices _ hich support the
growth and/or attachment of cellular materials.
As used herein, the term "'rotating wall batch-fed vessel"
shall refer to slow turning lateral vessel ISTLV_ and high50
aspect rotating vessel (HARVI.
As used herein, the term "'Corona Effecft'" shall refer to
the accelerated growth pattern of neuronal cells electrically
potentiated by waveform.
55 In one prelerred embodiment, the present invention is
directed to the growth of three dimensional mammalian
neuronal tissue using an electrically conductive strip in the
form of a channel or mold coated with a bioattractive or
biocompatable material to which an electrical potential is
60 applied to longitudinally orient the neural cells or axons as
they adhere to the bioattractive material which is suspended
in an axon rich medium.
A Specifically, in the present embodiment, the apparatus
includes a bioreactor chamber vessel employing electrically
(,5 insulative, biocompatable spherical disks of a material such
as silicon. These disks rotate inside the pressure vessel. Each
disk has multiple parallel channels cut into its surface. The
US 6,485,963 B l
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channels have a semicircular cross-section and contain an
electrically conductive inlay in the lbrm of a channel-shaped
conductive strip of a bioattractive material such as
zirconium, titanium and platinum. Each channel strip 6 has
an electrical contact on each longitudinal end that is used to
create and control an electrical potential along the length of
tile strip. The vessel is filled with a medium and the disks are
rotated within a medium containing axons. The cells adhere
to tile electrically conductive bioattractive inlay material.
The desired longitudinal cell orientation and tberefore the
structure of the resulting tissue is affected and/or controlled
by the electrical stimulus.
The present invention is also directed to the growth of two
dimensional mammalian neuronal tissue using electrodes.
The electrodes are either in direct contact or not in contact
`,vilh the target cells.
In one embodiment of the present invention, there is
provided a system for growing three dimensional mamma-
lian cells, comprising a rotating ',','all vessel containing a
cell-rich medium, cell carriers placed within the `,'essel and
an electrical potential applied to the cell c,'u-rier. Preferably.
tile rotating wall vessel can be a rotating wall peffused vessel
or a rotating ',`,'all batch-ted vessel.
In one embodimem of the present in`,'ention, the cell
carriers are spherical disks containing multiple parallel
channels, which are coated with a bioattractive material.
More preferably, the bioattractive material has a longitudinal
axis across which the electrical potential is applied. The
mammalian cells adhere to the bioattractive material and are
therefore oriented longitudinally upon the electrical stimu-
lus. Representative bioattractive materials include titanium.
zirconium and platinum.
In the methods of the present invention, the mammalian
cell is selected from the _oup consisting of a neuronal cell.
a normal human neuronal progenitor cell (NHNP) and a cell
responding to waveform. A person ha`,'ing ordinary skill in
this art will be able to apply the teachings of the present
invention to other cell types.
In another embodiment of the present invention, there is
provided a metht_ of culturing mammalian cells in the
claimed system, comprising the steps of inoculating the cells
into the vessel, rotating the vessel to initiate the attachment
of the cell to the cell carriers, applying an electrical potential
to the cell carriers and measuring the gro`,vth of the cells.
Preferably, the vessel is rotated at a speed from about 10
RPM to 30 RPM, and the electrical potential is applied at a
strength range of from about 1 mA to about 6 mA.
In still another embodiment of the present invention, there
is provided a system for _owing two-dimensional neural
cells, comprising a petri dish containing a cell culture
medium and an electrode placed in the center of the petri
dish. The electrode is charged with a waveform. Preferably,
the neural cells are bubbled directly' on the electrode. As a
result, the neutral cells exhibit accelerated growth.
in yet another embodiment of the present invention, there
is provided a system tot growing two-dimensional neural
cells further comprising a slide placed on the electrode.
Preferably, the neural cells are bubbled on the slide instead
of directly' contacting the electrode. Preferably, the wave-
form is applied at a strength range of from about I mA to
about 6 mA.
In still yet another embodiment of the present invention.
there is provided a method of treating an individual having
diseased neuronal cells, comprising the steps of grov,,ing
neuronal cells in the two or three dimensional systems
disclosed herein and transplanting tile _own neuronal cells
8
into the indixidual. Such diseases include Parkinson's
disease, diseases of neuromuscular junction and Alzheimer's
Disease. Neural trauma can also be treated with this same
methodology.
5 In yet another embodiment of the present invention, the
waveform lot electrical potentiall induces a cellular
response including cellular control of growth and differen-
tiation at gene le`,'e]. Preferably'. the cellular control of
growth and differentiation is to suppress or enhance growth
l0 regulatory' functions at gene level. Still preferably, the gene
is associated with embryogenesis.
The following examples are given for the purpose of
illustrating various embodiments of the inx'ention and are
not meant to limit the present invention in any fashion.
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EXAMPLE 1
Cells
Normal human neuronal progenitor cells (NHNPI `,_ere
pooled from three donors. As controls, normal human neu-
20 ronal progenitor cells were _own in conventional tissue
culture following standard cell culturing procedures.
EXAMPLE 2
Materials
GTSF-2 medium with 10'5 FBS, Ciprofloxacin and Fun-
25 gizone was used to culture the cells. IxPBS, Collagenase,
DNase and Trypsin `,,,'ere purchased from Clonetics. The
cells were grown on 12-100 mm Petri dishes (tissue culture
coated or not coated). Electrodes were made of platinum and
stainless steel. A wa`,'elorm generator was used to generate
30 the waveform in a strength of 1-6 mA (AC) square wave, 10
Hz variable duty cycle.
EXAMPLE 3
Electrically Potentiating Cell Growth When Electrode is in
._5 Direct Contact with the Target Cells
Initially', a metal electrode was placed thside a petri dish
and centered.
Normal human neuronal progenitor cells were seeded at
2><,10s cells in 0.7 ml of media and carefullx dropped on the
40 electrode m a concentrated bubble (FIG_ 1). Cells were
incubated for 2 days. Second day' after seeding is considered
day 0 of the experiment. At day' 0, each dish was given 15
ml of media and wavelbml was applied to seven electrodes.
Cells `,`,,ere observed under a dissecting microscope and fed
45 with 15 ml of media at dav 3, and 13 ml every three days at
day 6, O and 12. At day 14, the cells were led again with 13
ml of media. At day 17, the cells were incubated lot 10
minutes in a Collagenase/DNase cocktail, then trypsin was
directly applied to the cocktail and the cells were further
5o incubated for 3 more minutes. Before tile media was added
to deactivate trypsin, the cocktail mix was pipetted up and
down several times. The cells were washed twice with
I×PBS, reapplied with the media and placed on ice. The
cells were counted, assessed for viability.
55 To examthe the accelerated growth of cells 48 and 72
hours after waveform was discontinued, cells were treated
the same as above, except thai after day 14 treatment, instead
of harvesting, two dishes from the non-wavefornl group
(control) and two dishes from the waveform group were
e,0 randomly chosen and re-seeded at 9×105 cells in two new
petri dishes each, with a total of four dishes. Cells from one
set (#11 ;vaveform anti control #6) were counted and pho-
tographed 48 hours after seeding, and cells from the second
set (#12 waveform and control #7) were counted and pho-
65 tographed 72 hours after seeding.
To examine accelerated growth pauern "'Corona Effect"
after the electrical potentiation, the same treatment was
US 6,485,963 B l
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applied to the cells without harvesting. A dish each from
wavetorm group and non-waveform group were chosen
randomh'. Cells still attached in sheet from were lifted off of
the electrodes carefully and placed in new petri dishes with
medium, and then photo_aphed 24 hours later. 5
EXAMPLE 4
Electrically Potenliatiny Cell Growth When Electrode is not
iu Direct Contact with the Target Cells
Initially. a metal electrode was placed inside a petri dish
and centered. A slide was c,-u'efully placed on the electrode
under sterile conditions. Normal human neuronal progenitor
cells were seeded at 2×10 s cells in 0.7 ml ot media and
bubbled on the slide. Cells were incubated for 2 days. 25 ml
of media were applied and two 1000 _tl pipetman blue tips
were placed in the dish to anchor the slide to bottom of the
dish. The second day after seeding was considered day 0 of
the experiment. At day 0, each dish was given 25 ml of
media and waveform was applied to six of the twelve
electrodes.
Cells were observed under a dissecting microscope and
fed with 25 ml of media every three days at day 3.6, 9 and
[2. At day 14, the cells were fed again with 25 ml of media.
At day 18. the cells ,,,,'ere incubated for 10 minutes in a
Collagenase/DNase cocktail, then typsin was directly
applied to the cocktail and the cells were further incubated
for 3 more minutes. Before the media was added to deac-
tivate trypsin, the cocktail mix was pipetted up and down
several times. The cells were washed twice with I×PBS,
reapplied with the media and placed on ice. The cells were
counted, assessed lor viability and then replated at 100,000
per plate. The remaining waveform and non waveform slides
were fixed and refrigerated [or staining at a later date.
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TABLE l-continued
*Cell Counl andViabilit'. at Harvest _dax 17J
NHNP-POOI CELL COUN'] VIABILITY HARVEST
Waveionn 10 1.000.000 OSQ 17 da3s
Control I 500.000 OSG- 17 da) s
Control 2 400.000 q'8 c, 17 da.',_,
Control 3 300000 98G 17 da}s
Control 4 500.000 98G 17 da', s
Control 5 400.000 08 c, I7 da?.s
*Cells were in direct contact with the electrode
t5 TABLE 2
2o
25
EXAMPLE 5 35
Electrically Potentiated Growth of Cells
Normal human neuronal progenitor-pool cells exposed to
a time varying electromagnetic field (waveforml, either in
direct contact or not in direct contact with the electrode,
displayed an accelerated growth rate and different morphol- 4o
ogy as compared to non waveform cells (control), i.e.. cells
not subject to the time varying electromagnetic field (see
Table 1 and Table 2, FIGS. 2,--9). After the application of the
time varying electromagnetic field or waveform, the cells 45
prelerentially aligned, while cells without waveform expo-
sure showed random pattern. Cells in direct contact with the
electrode remained stimulated up to at least 72 hours after
wa``'eforn was removed (Table 31; while those not in direct
contact with the electrode once removed from waveform
continued to experience accelerated and long term stimula- 5o
tion growth pattern even after 168 hours (Table 4). Viability
was also higher in the cells exposed to the waveform (Table
4 }. Cells were suspended easily with the Collagenase/DNase
then trypsin sequence.
TABLE I
'(ell ('otmt and Viabilit', at Harxest Ida',' 17)
_Cell Count and Viabilir, at Ha_rest Ida', 18)
NHNP-P(X)L CELL COUNT VIABILITY HARVEST
NHNP-POOL CELL COUNT VIABILITY HARVEST
Wavelonn I 1,000.000 100% IS da?.s
_,Va,,elonn 5 1.100.000 lOOCc IS days
('ontrol 1 800,000 100G IS dass
Control 5 800.000 10OG 18 da_,',
*Cells were not in direct contact v,,ith the electrode
TABLE 3
*Cell Count at k'arious Tnnes alter Removal of \Va_etonn
Wa_efonn I 860.000 98% 17 days
V,,'a,,'eionn 2 1.000,000 98q 17 days
Wa_efonn 3 1.000.000 98% 17 days
Wavefon'n 4 1.300.000 08% 17 days
\Va_elomt 7 1,000,000 98c_ I7 days
Wavefonn 8 040,000 98c, - 17 days
"Waveform 9 700,000 08_ 17 days
30 CELLS COUNT HOURS OFE ELECTRODE
Wavefoml 1I 520.000 Counted and re-seeded at q6.000/plate
Control 6 112.000 Counted and re-seeded at 96,000/plate
Waveform I I 274.000 48 hours off electrode
Control 6 48.000 48 hours off electrode
Wa_efonn 12 576.000 Counted and re-seeded at 96.000/plate
Control 7 96.000 Counted and re-seeded at O6.000/plate
Wavetorm 12 228.000 72 hours off electrode
Control 7 120,000 72 hours off electrode
:1Cells were m direct contact with the electrode
TABLE 4
*Cell Count attd Viabilir, at Various rimes after Har',est
TIMqE AFTER
HARVEST
NHNP-POOL CELL COUNT VIABILITY (Hours_
55
6O
Wavefonn 1 56.0(O 85% 24
Wavefonn 5 40.0(K_ 85% 24
Control 1 30,000 _55c_ 24
Control 5 28,000 65G 24
Wa',efoml 1 I S_.O00 98G 48
War efonn 5 212,000 08% 48
Control I 74,000 87% 48
Control 5 162,000 9Oct 48
Wa_ efom_ 1 3.400.000 IOOG 120
Waveform 5 3.400,000 100% 120
Control I 900.000 00% 120
Control 5 900.000 OOG 120
kVavefonn 1 4.000.000 100q 168
_,'ave form 5 3,800,000 100% 168
Control 1 980,000 07% 168
Control 5 000.000 05"( 168
(:,5
:+(ells xsete nol in direct contact with the electrode
EXAMPLE 6
Waveform Gene Array Display, (GAD) Results
Normal Human Neural Progenitor cells or human adult
astrocytes were exposed to waveform and non-``va``'eforrn
growth conditions for 17 days. Upon completion of the
US 6,485,963 B1
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exposure period cells were harvested via trypsinization and
poly-RNA was prepared from the respective groups of cells.
RNA samples were quick frozen and shipped to Synteni
Corporation for GAD analysis. Below are the results of a
survey of the response of over 10,000 human genes. The 5
results were divided into two categories _Table 5 and Table
6 i. Those genes down regulated or suppressed by the wave-
form and those up regulated or enhanced in activity by the
waveform.
An analysis of the data indicates a significant down 10
regulation of maturation and regulatory' genes. These matu-
ration and regulator.', genes are normally associated with the
differentiated or non-growth profile of normal cells.
However, there is a significant up regulation of some 150
genes which are mainly associated with growth and cellular
15
proliferation. Neither two nor three dimensional growth of
neural cells has been achieved prior to this event with the
positive outcome of enhanced Uowth and apparent gene
regulatory control.
TABLE 5 20
Down Regulated Genes in Descending Order IHighest to
lowest
1. Homo sapiens (clone Zap2_ mRNA fragment [incyte
PD: 1661837 ]
2. CDC28 protein kinase 2{Incyte PD: 1384823] 35
3. Synteni: YCFR 22 {YC 22.2000.W]
4. ESTs, Moderateb similar to cell growth regulating nucle-
olar protein LYAR [M.musculus] {lncyte PD:2233551]
5. KERATIN, TYPE II CYTOSKELETAL 7 {Incyte
PD: 1(-,4.9959] 3o
6. MITOTTC KINESIN-LIKE PROTEIN-I {lncyte
PD:2640427 ]
7. EST {incyte PD:674714}
8. Synteni: YCFR 22 [YC 22.2000.X}
9. Synteni: YCFR 26 {YC 26.0062.N} 35
10. Synteni: YCFR 22 {YC 22.2000.Z}
11. Transcription factor 6-like 1 (mitochondrial transcription
factor l-like_ {Incyte PD:3371995}
12. interferon-inducible 56-KDa protein {Incvte
PD: 1215596} 40
13. EST {incyte PD:1794375]
14. Homo sapiens mitotic feedback control protein Madp2
homolog mRNA, complete cds {Incyte PD:2414624}
15. EST {incyte PD:151026}
16. Homo sapiens Pig3 (PIG3) mRNA, complete cds 45
{lncyte PD:2395269}
17. General transcription factor IliA {Incyte PD: 1527070]
18. Cellular retinoic acid-binding protein [human, skin,
mRNA, 735 nt] {Incyte PD:585432}
It). EST {Incyte PD:1755159] 50
20. Homo sapiens mRNA for KIAA0285 gene. complete cds
{Incyte PD:1738053}
21. ESTs, Weakly similar to F25H5.h [C.elegans] {lncyte
PD: 1923567}
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31. Adenylosuccinate lyase {lncyte PD:1653326]
32. EST {lncyte PD:1798393]
33. Homo sapiens HP protein (HP_ mRNA, complete cds
{lncyte PD:30841223 }
34. ESTs. Moderately' similar to TlOC6[C.elegans] [Incy'te
PD: 1923186]
35. Chromosome condensation 1 {Incyte P1):3180854}
36. Cahnodulin 1 Iphosphorylase kinase, deltal {lncyte
PD:2803306]
37. Centromere protein A I 17kDi {Incyte PD:2444942]
38. V-jun avian sarcoma virus 17 oncogene homolog {Incyte
PD: 1920177 }
39. Human glutathione-S-transferase homolog mRNA, com-
plete cds {lncyte PD:1862232}
40. Homo sapiens gene tor protein involxed in sexual
development, complete cds {Incyte PD:3033934]
41. EST {Incyte PD:2630992}
42. Human low-Mr GTP-binding protein IRAB321 mRNA,
partial cds [lncvte PD:1662688}
43. Annexin II! (lipocortin I11) {Incyte PD:1920650}
44. Hydroxymethylbilane synthase {Incyte PD:1509204}
45. Synteni: HK 4 {HK 4.2000.Y]
46. Ribosomal protein L7a {lncyte PD:2579602]
47. Human mRNA for myosin regulatory light chain [Inc,vte
PD:78783]
48. Ferredoxin reductase {incyte PD:1819763]
49. Human copper transport protein HAH 1 (HAH 1I mRNA,
complete cds {lncyte PD:2313349]
50. Human G protein gamma- 11 subunit mRNA, complete
cds {lncyte PD:1988432}
51. Synteni: HK 4 {HK 4.2000.W]
52. Human XIST, coding sequence a mRNA (locus
DXS399El {lncyte PD:1514318}
53. Ribosomal protein, large, P0 {Incyte PD:3511355}
54. Homo sapiens clone 23714 mRNA sequence {lnc.vte
PD: 1728368}
55. Human mRNA for Apol_3 Human IMER51Aopl-
Mouse)like protein I, complete cds {Incyte PD:2527879}
56. Synteni: HK 4 {HK 4.2000.Z]
57. Proteasome (prosome, macropain) subunit, beta type, 5
{lncyte PD:2503119]
58. Human PINCH protein mRNA, complete cds {Incyte
PD:126888}
59. Homo s_q_iens peroxisome assembly protein PEXIO
mRNA, complete cds {tncyte PD:998279}
60. Homo sapiens short chain L-3-hydroxyacyl-CoA deh 3-
drogenase (SCHAD) mRNA, complete cds {lncyte
PD: 1638850]
61. Neuroblastoma RAS viral tv-ras) oncogene homolog
{lncyte PD:2816984}
62. H.sapiens mRNA for b4 integrin interactor {lncyte
PD: 1932850]
63. Human forkhead protein FREAC-I mRNA, complete
cds {Incyte PD:1449920]
22. Homo sapiens mRNA expressed in osteoblast, complete 55 64. Human mRNA for protein D123, complete cds {incyte
cds [lncvte PD:2537863] PD: t o'_o_'__ i
23. EST [Incyte PD:3204745] 65. H.sapiens mRNA for A-kinase anchoring protein
24. Homo sapiens mRNA for serine/threonine protein kinase AKAP95 {Inc.vte PI): 1628787 ]
.'3 _ ISAK {lncyte PD.,73,630j 66. Carbonyl reductase {Incyte PD:1633240]
25. Homo sapiens serum-inducible kinase mRNA, complete 60 67. EST [Incyte PD:2060073}
cds {lncyte PD:1255087]
26. Carbonic anhydrase 1I [lncyte PD:2474163]
27. EST {Incyte PD:660376}
28. GRANCALCIN {Incyte PD:1671852]
29. N-CHIMAERIN {Incyte PD:1852659]
30. Homo sapiens Pig l0 (PIG I0) M3RNA, complete cds
{lncyte PD:I731061 }
65
68. ESTs, Highly similar to GUANINE NUCLEOTIDE-
BINDING PROTEIN Gtl)/G(S#G(OI GAMMA-7 SUB-
UNIT [Rattus m_n'egi_'uq { lncyte PD: 1640161 ]
69. Homo sapiens Na+/Ca+exchanger mRNA sequence
{Incyte PD:2880435}
70. STRESS-ACTIVATED PROTEIN KINASE JNK1
{incyte PD:3331710]
US 6,485,963 B I
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71. Homo supien_' leupaxin mRNA, complete cds [Incyte
PD: 1595756]
72. CLEAVAGE SIGNAL-I PROTEIN [Incyte
PD:2054053]
73. EST [lncytc PD: 1798065] 5
74. Human DNA from overlapping chromosome 19 cosmids
R31396, F2545 I. and R31076 containing COX6B and
UPKA. genomic sequence {Incyte PD: 1320685 }
75. INTERFERON-INDUCED 17 KD PROTEIN [Incyte
PD:2862071 ] lo
76. Human homolog of ,,'east IPP isomerase [Incyte
PI): 15262401
77. Translation elongation factor 1 gamma {lncyte
PD:3138196}
78. Tropomyosin alpha chain Iskeletal muscle_ [lncyte 15
PD: 1572555}
70. Aplysia ras-related homolog O [Incyte PD:2733928}
80. ATP SYNTHASE ALPHA CHAIN. MITOCHON-
DRIAL PRECURSOR [incyte PD:3206210]
81. Homo s_q_iens androgen receptor associated protein 24 20
IARA24J mRNA, complete cds [Incyte PD:552654]
82. Glucagon [Incyte PI):1333075 ]
83. Human enhancer of rudimentaLv homolog mRNA, com-
plete cds [Incyte PD:1704472]
84. TRANSCRIPTIONAL ENHANCER FACTOR TEF-I 25
[lncyte PD:2957175 ]
85. Ubiquitin-like protein [Incyte PI):1754454]
8,6. Human RGP4 mRNA, complete cds {Incyte
PD:617517]
87. Cellular retinol-binding protein [Incyte PD:1612969} 30
8_,. Ornithine decarboxylase 1 {lncyte P1):1930235}
89. EST [Incyte PD:3605632}
90. EST {lncyte PD:2057260}
91. ESTs, Weakl 3 similar to CAMP-DEPENDENT PRO-
14
109. Human mRNA for proteasome subunit HsC 10-II. com-
plete cds [Incyte PD:1737833}
110. Homo sapiens mRNA for STI C2, complete cds
[lncyte PD:3993007]
Ill. Human dual specificity phosphatase lyrosine/serine
mRNA, complete cds [Incytc PD: 1514573}
112. Human stimulator of TAR RNA binding _SRBI mRNA,
complete cds [Incy'te PD:2057162]
13. EST {lncyte PD:2507206}
14. H.sapie_rs mRNA for Ndr protein kinase [lncyte
PD:33185711
15. ESTs, Weakly similar to Grb2-related adaptor protein
[H.sapiens] {lncyte PD: 1857259]
16. EST,, Highly similar to Tbcl [M.musculus] [Incytc
PD: 1889147 }
17. GTPase-activating protein ras p21 (RASA) [incyte
PD: 147344]
18. Human mRNA for KIAA0123 gene, partial cds [ lncyte
PD: 1752436}
19, Svnteni: YCFR 22 [YC 22.2000.Y]
20. Human non-histone chromosomal protein (NHCJ
mRNA. complete cds [Incyte PD:17486701
121. Thioredoxin [lncyte PD:2606240]
122. FATTY ACID-BINDING PROTEIN, EPIDERMAL
[Incyte PD:2537805 }
123. Proteasome component C2 {lncyte PD:2195309]
124. Homo sapiens heat shock protein hslM0 homolog
mRNA, complete cds [lncyte PD:2844980]
125. Human amyloid precursor protein-binding protein 1
mRNA, complete cds [lncyte PD:1663083]
126. Homo sapiens DNA binding protein homolog _DRILI )
mRNA, complete cds {Incyte PD:2538333]
127. Human Has2 mRNA, complete cds [lncyte
PD:3602403]
TEIN KINASE TYPE 2 [Sacc/raromyces cerevi.siae] 35 128. EST [Incyte PD:1740678]
[lncyte PD:2055611 ]
92. Human p37NB mRNA, complete cds {Incyte
PD: 1407110}
93. Human mRNA for suppressor for yeast mutant, complete
cds [Incyte PD:2888814]
94. EST [Incyte PD:3142705]
95. ESTs, Weakly similar to KOI H 12. l [C.elegans] [Incyte
PD:56197}
96. Cell division cy,cle 2. G I to S and G2 to M {Incyte
PD: 1525795]
97. EST [Incyte PD:1794175}
98. EST [incyte PD:14895571
99. ESTs, Weakly similar to PROTEIN PHOSPHATASE
PP2A, 72 KD REGULATORY SUBUNIT [H.sapiens]
[lncyte PD:23790451
100. CAMP-DEPENDENT PROTEIN KINASE TYPE
II-ALPHA REGULATORY CHAIN {Incyte
PD: 1(_t9731 }
101. ESTs, Weakly similar to transcription factor
[H.sapietrq [ Incyte PI):1637517}
102. ATP synthase, H+transporting, mitochondrial FI
complex, O subunit (oligomycin sensitivit5 conferring
protein) [Incyte PD:2193246}
103. RAg-LIKE PROTEIN TC21 [lncyte PD:2505425]
104. Small nuclear ribonucleoprotein polypeptides B and B I
[Inc.vte PD:2071473]
105. EST {Incyte PD:1922084}
106. Proliferating cell nuclear antigen {incyte PD:2781405 }
107. ESTs. Highly similar to HIGH MOBILITY GROUP-
LIKE NUCLEAR PROTEIN 2[Saccharomyces
cererisiae] {incytc PD:2669174]
108. EST [Incyte PI):184415(1}
129. Homo sapiens golgi SNARE {GS27_ mRNA, complete
cds {Incyte PD:3279439]
130. ESTs, Weakly similar to UBIQUITIN-ACTIVATING
ENZYME El HOMOLOG [H.sapiel_s] {Incyte
4o PD: 1710472]
131. Synteni: YCFR 22 {YC 22.2000N]
132. Voltage-dependent anion channel 2 {Incyte
PD:2189062]
133. Human rap2 mRNA for ras-related protein [Incyte
,;5 PD:3334979]
134. Acid phosphatase 1, soluble [Incyte PD:620871 }
135. Human clone 23840 mRNA, partial cds [Incyte
PD: 1830083]
136. Human mRNA for KIAA0008 gene, complete cds
5o [Incyte PD:I97011 I]
137. H.sapiens mRNA for protein-tyrosine-phosphatase
_tissue Lvpe: foreskin) [Incyte PD:_957]
138. Human B-cell receptor associated protein (hBAPI
mRNA, partial cds {Incyte PD:2545562}
55 139. ESTs, Highly similar to ring finger protein [H.sapiens]
{lncyte PD:2860918}
140. H.sapiens mRNA for CLPP [Incyte PD:2675481 }
141. APOPTOSIS REGULATOR BCL-X [lncyte
PD: 1855683]
60 142. PROTEASOME COMPONENT CI3 PRECURSOR
[Incyte PD:2668334]
143. Sorting nexin I {Inc3te PD:1508407]
144. Human voltage dependent anion channel form 3
mRNA, complete cds {lncyte PD:2051154]
65 145. H._apiens mRNA for translin {lncyte PD:986855}
146. Human DEAD-box protein p72 (P72) mRNA, com-
plete cds {Incyte PD:1750553]
US 6,485,963 B I
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147. Ras homolog gene l_amily, member G _rho GI [lncyte
PD: 1342744]
148. EST {lncyte PD:1377794]
149. Human FEZ2 mRNA, partial cds [lncyte PD:2623268}
150. Human homolog of Drosophil_ discs large protein,
isoform 2 (hdlg-2) mRNA, complete cds [lncyte
PD:2203554]
151. ALCOHOL DEHYDROGENASE [lncyte
PD: 1634342]
152. 3-hydroxynaethyl-3-methylglutaryl-Coenzyme A lyase
Ihydroxymethylglut,'n-icaciduria I [ Incyte PD: 1695917}
153. ENOYL-COA HYDRATASE, MITOCHONDRIAL
PRECURSOR [Incyte PD:2235870]
154. Proteasome _prosome, macropain) subunit, beta type, 6
[Incyte PD:2989852]
155. INTERFERON GAMMA UP-REGULATED 1-5111
PROTEIN PRECURSOR {Incyte PD:2211625]
156. Epimorphin [Incyte PD:3438987}
157. H.sapiens R'Y-I mRNA for putative nucleic acid bind-
ins protein [Incyte PD: 1805712]
158. EST [lncyte PD:1905120]
159. KD HOUSEKEEPING PROTEIN [Incyte
PD: 1819287 ]
160. Cytochrome c oxidase subunit Vllb {Incyte
PD:2060789 }
161. EST [lnc.vte PD:661516]
162. Homo s_q_iens nuclear VCP-like protein NVLp.2
_NVL.2i mRNA, complete cds (Incyte PD:1445507]
163. EST [incyte PD:1251588)
164. EST [Incyte PD:1665871}
165. Homo stq_iens inosito] polyphosphate 4-phosphatase
type l l-alpha mRNA, complete cds line.vie
PD:3032739]
166. Homo sapiens arsenite translocating ATPase (ASNA 1
mRNA, complete cds {Incyte PD: 1666094]
167. Human SnRNP core protein Sm D3 mRNA, complete
cds [ lnc.vte PD: 1624865 ]
168. Homo sapiens clone 23777 putative taansmembrane
GTPase mRNA, partial cds [lncyte PD:2554541 ]
169. Hmno salfiens regulator of G protein signaling RGSI2
(RGSJ mRNA, complete cds [Incyte PD:3618382]
170. Human Ki nuclear autoantigen mRNA, complete cds
[Inc.vte PD: 1308112}
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8. ESTs, Weakly similar to metaxin [H.sapiens] {incyte
PD: 1754461 ]
9. Plasminogen [lncyte PD:25 t5873}
10, Human mRNA for CC chemokine LARC precursor.
5 complete cds [Inc.vte PD:2220923]
I1. S.vmeni: YCFR 21 {YC 21.0062.N_
12. Homo sapiens Amplified in Breast Cancer _AIBIi
mRNA, complete cds Incyte PD:2634.478}
13. Homo sapien_ clone 24640 mRNA sequence {lncyte
Io PD:1560143]
14. Svnteni: YCFR 21 {YC 21.2000.N]
15. EST [lncyte PD:143912]
16. Human transcription [actor SIM21ong torm mRNA.
complete cds {Incyte PD:996104]
15 17. EST [Incyte PD:2841478]
18. PUTATIVE DNA BINDING PROTEIN A20 [Incyte
PD:1878791}
19. Protein tyrosine phosphatase, receptor type. mu polypep-
tide [Incyte PD:987736]
20 20. Human clone A9A2BRB5_CAC)n/_GTGm repeat-
containing mRNA [Incyte PD: 1987975]
21. Endothelin con\erring enzyme 1 [Incyte PD: 1063819]
22. BBI [lncyte PD:1966148}
23. Pleiotrophin Iheparin binding growth factor 8, neurite
25 growth-promoting tactor 1_ [Incyte PD:2989411 }
24. Argininosuccinate synthetase {lncyte PD: 1981145 ]
25. Human breast epithelial antigen BA46mRNA. complete
cds [Incyte PD:1319020]
26. Human clone 46691) brain expressed mRNA from chro-
3o mosome X [incyte PD:1669780}
27. Human plectin IPLECI _mRNA, complete cds [Incyle
PD: 1907232]
28. HomrJ sapiens mRNA for calmegin, complete cds
[lncyte PD:2498216]
35 29. EST [Incyte PI):769182}
30. Amyloid beta IA4_ precursor-like protein 2 [lncyte
PD:38767151
31. Polymerase {RNA! II (DNA directedt polypeptide A
{220 kD _ {Incyte PD:1382059}
4o 32. GLUCOSE TRANSPORTER TYPE 3, BRAIN [Incyte
PD:2745082}
33. Homo sapiens sarc¢_-/endoplasmic reticulum Ca-ATPase
3 (ATP2A3} mRNA, alternatively spliced, partial cds
171. Homo sapiens peroxisomal phytanoyl-CoA alpha- [Incvte PD:688411]
hydroxylase IPAt-tX) mRNA, complete cds [lncyte 45 34. Human c-jun prolo oncogene tJUNI, complete cds, clone
PD:4073867} hCJ-I [lncyle PD:1969563}
172. PLACENTAL CALCIUM-BINDING PROTEIN
{Incyte PD. I,__317j
173. PRE-MRNA SPLICING FACTOR SF2, P32 SUB-
UNIT PRECURSOR {Incyte PD:1552335}
174. Human clone C4E 1.63 _CACln/tGTGln repeat-
containing mRNA [incyte PD:1928789}
175. Human glioma pathogenesis-related protein _GliPR_
mRNA, complete cds [Incyte PD:477045}
176. Homeo box A9 [Incyte PD:459651]
TABLE 6
Waveform Up Regulated Genes in Ascending Order (Lowest
to Highest_
I. NEUROMEDIN B PRECURSOR [Inc._te PD:2754315]
2. Synteni: YCFR 21 {YC 21.0031.N]
3. ATRIAL NATRTC PEPTIDE CLEARANCE RECEP-
TOR PRECURSOR {lncyte PD: 1353606}
4. Synteni: YCFR 85 {YC 85.2000.Y}
5. Homo sapiens CHD3mRNA, complete cds [lncyte
PD: 1965248]
6. EST [Incyte PD:565872]
7. Synteni: YCFR 46 Cy3 [YC 46.2000. Z}
35. Microtubule-associaled protein 1A [incyte PD:702684]
36. Clusterin tcomplement lysis inhibitor, testosterone-
repressed prostate message 2: apolipoprotein J) {lncyte
5o PD:2966620]
37. NADH-CYTOCHROME B5 REDUCTASE {Incyte
PD:I901142}
38. Protein-tyrosine kinase 7 [lncyte PD:996229]
39. Alpha-1 type XVI collagen -[lnc.vte PD: 1963529]
55 40. EST [Incyte PD:2839121]
41. Homo sapiens mRNA for DEC 1, complete cds [lncyte
PD: 1732479]
42. Hunmn endogenous retroviral protease mRNA, com-
plete cds {Incyte PD:1347636]
_o 43. ATPase, Na+/K+transporting, alpha lpolypeptide
[Incyte PD:1730609]
44. Laminin,alpha 4 {[ncyte PD:1851696}
45. Hexabrachion !tenascin C, cytotactin) [Incyte
PD: 1453450}
_5 46. Human mRNA for KIAA0325 gene, partial cds [Incytc
PD: 1995315]
47. lntegrin beta-5 subunit {lncyte PD:418731]
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48. Microfibrillar-associated protein 4 {lncyte PD:1659231 ]
49. Fibulin I [Incytc PD:1320658}
5(1. Protein serine/threonine kinase stk2 {lncyte
PD:1518981 ]
51. ESTs, Weakly similar to HYPOTHETICAL 16.1 KD s
PROTEIN IN SEC 17-QCRI INTERGENIC REGION
[Saccharomyces ccrevisiae] {lncyte PD: 1923722 }
52. Homo sapiens carbonic anhydrase precursor (CA 121
mRNA. complete cds [lncyte PD:3766382]
53. H.sapiens mRNA for SIXI protein [Incyte J0
PI): 32(18486 ]
54. Plasminogen activator inhibitor, type I [lncyte
PD: 1445767]
55. Human mRNA for SHPS-I, complete cds {lncyte
PD:2 18(t684] 15
56. Collagen, type V, alpha I [Incyte PD:1672442}
57. Homo sapiens monocarboxylate transporter (MCT3_
mRNA, complete cds [Incyte PD:1343253]
58. Human follistatin gene [lncyte PD:1577614}
59. Human putative RNA binding protein (RBP56_ mRNA, 2o
complete cds [incyte PI): 1907369]
60. Homo sapien._ mRNA for PRP8 protein, complete cds
[Incyte PI):3616229]
61. Homo sal_iens CAGH 13 mRNA, complete cds {Incyte
PD: 1432042} 25
62. EST [Incyte PI):2953888]
63. Intercellular adhesion molecule 1 ICD54_, human rhi-
novirus receptor [ lncyte PD: 1556061 ]
64. Human p 120E4F transcription factor mRNA, complete
cds [lncyte PD:1940164}
65. Collagen, type VI, alpha I [lncyte PD:2672056]
66. Human mRNA for pM5 protein [Incyte PD: 1578951 ]
67. ALZHEIMER'S DISEASE AMYLOID A4 PROTEIN
PRECURSOR [ lncyte PD: 126370}
68. Human mRNA for KIAA0062 gene, partial cds {Incyte 35
PD:3138128]
69. Human clone HSH 1 HMG CoA synthase mRNA, partial
cds {Incyte PD: 1807407}
70. Filamin 1 (actin-binding protein-280 {Incyte
PD:1708528_ 4o
71. Synteni: YCFR 85 [YC 85.2000.X]
72. Synteni: YCFR 46 Cy3 [YC 46.2000.W]
73. Homologue of mouse tumor rejection antigen gp96
{lncyte PD:2679349]
74. Tissue inhibitor of metalloproteinase 3 {Sorsby fundus 45
dystrophy, pseudoinflammatory ) [ Incyte PD:418041 ]
75. Human XMP mRNA, complete cds [Incyte
PD: 1887661 ]
76. Cylochrome P450. subfamily X1A (cholesterol side
chain cleavage_ Ilncyte PD:2368282]
77. Granulin [lncytc PD:812141]
78. Human extracellular matrix protein I (ECMI) mRNA,
complete cds [ Incyte PD: 1965806}
79.78 KD GLUCOSE REGULATED PROTEIN PRECUR-
SOR {lncyte PD:2884613]
80. Synteni: YCFR 21 [YC 21.2000.X}
81. Homo sapiens mRNA for serin protease with IGF-
binding motif, complete cds {incyte PD:1958902]
82. Inhibitor of DNA binding 1. dominant negative helix-
loop-helix protein [lncyte PD: 1687(160]
83. Solute carrier family 6 Ineurotransmitter transporter,
taurine), member 6 {lncyte PD: 1516886}
84. Hormone receptor (growth factor-inducible nuclear pro-
tein NI(B {lncyte PD:1958560}
85. Fibulin 2 {lncyte PD:1901095]
86. Kinase insert domain receptor (a type III receptor
tyrosine kinase) [Incyte PI):2220338]
18
87. Svnteni: YCFR 45 [YC 45.2000.X]
88. Syndecan 4 (amphiglycan, ryudocanl {Incyte
PD:3214670]
89. Svnteni: YCFR 2t [YC 21.0500. N]
90. Human pre-B cell enhancing factor (PBEF! mRNA,
complete cds {Incyte PD:1641590]
91. Cytochrome P450, subfamily IIC lmephenytoin
4-hydroxylase t [lncyte PD:168865 }
92. Latent transfornfing _owth factor beta binding protein
l [lncyte PD:1313183]
93. Lysyl hydroxylase [Incyte PD:1759127}
94. Human mRNA for KIAA0230 gene, partial cds [Incyte
PD: 1449824}
95. Human mRNA for dihydropyrimidinase related protein-
2, complete cds [Incyte PD:2784546]
96. H.sapiens garp gene mRNA. complete CDS (Incyte
PD:3572014]
97. EST [lncyte PD:724880]
98. ESTs. Weakl3 similar to TRANSMEMBRANE PRO-
TEIN SEX PRECURSOR [H.sapiens] [lncyte
PD: 1511346]
99. Human contactin associated protein (Caspr_ mRNA,
complete cds [lncytc PI):2309047]
100. Human cvsteinc-rich fibroblast growth factor receptor
(CFR-II mRNA. complete cds [Incyte PD:2204871 }
10t. EST [Incyte PD:2580841]
102. Collagen, type V, alpha [Incyte PD:I887t)59]
103. H.sapien_s RNA for type VI collagen alpha3 chain
[Incyte PI): 1314882}
3o 104. Protein kinase C substrate 80K-H [Incyte
PD: 1723971 ]
105. Fibrillin 1 t Marfan s.vndrome _ [Incyte PD: 1448051 ]
106. Collagen, type XI, alpha 1 [lncyte PD:3598222]
107. H.sapiens mRNA for extracellular matrix protein col-
lagen type mV, C-terminus {lncyte PD:220899(1]
108. Collagen, type II, alpha 1 (primary osteoarthfitis.
spondyloepiphyseal dysplasia, congenital l [Incyte
PD:2518178]
109. ESTs, Weakly similar to unknown [S.cerevisiae]
[ lncyle PD:2171401 ]
110. EST {lncyte PD:1923572}
I11. Human insulin-like growth factor binding protein 5
t IGFBP5 ) mRNA [incyte PD: 1686585 ]
112. Human mRNA for KIAA0242 gene, partial cds [lncyte
PD: 1940994 ]
113. Complement component 1, s subcomponenl {incyte
PD: 1904751 ]
114. Human chromosome 17 unknown product mRNA.
complete cds [Incyte PD:2849603}
5o 115. Homo sapiens lysosomal pepstatin insensitive protease
(CLN2) mRNA. complete cds {Incyte PD:350(t996 ]
116. Collagen, type IV, alpha 2 {Incyte PD:1906574]
I17. ESTs, Moderately similar to ZINC FINGER PROTEIN
HF. 12 [Homo sapiens] {lncyte PD:3729155 ]
55 118. Homo sapiens stanniocalcin precursor (STCI mRNA,
complete cds [Incyte PD:2222921 )
119. P55-C-FOS PROTO-ONCOGENE PROTEIN {incyte
PD:341491 }
120. EST [lncyte PI):2424631 }
60 121. EST [Incyte PD:1940710]
122. Thrombospondin 1 [lncyte PD:2055534]
123. Complement component C Ir {Incyte PD:1664320]
124. REGULATOR OF G-PROTEIN SIGNALLING
2{tncyte PD:1218114]
6s 125. INTEGRAL MEMBRANE PROTEIN El6 {Incyte
PD:I911012}
126. Collagen, type 1, alpha 1 {lncyte PD:782235]
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127. H.sapiens mRNA for adipophilin [Inc3,te PD: 1985104}
128. EST [Incyte PD:1979450]
129. EST [tncyte PD:600994]
130. Cathepsin D (lysosomal asp,'u-tyl protease) {incyte
PD:3940755 ]
131. Matrix metalloproteinase 2 (gelatinase A, 72 kD
gelatinase, 72 kD type IV collagenase) [[ncyte
PD: 1558081 ]
132. Cyclm D2 [lncy, te PI):16184221
133. EST [lncyte PD:2636514]
134. COMPLEMENT C3 PRECURSOR [Incyte
PD: 1513980]
135. Homo sapiens secreted frizzled related protein mRNA,
complete cds [lncyte PD:428236]
136. INSULIN-LIKE GROWTH FACTOR BINDING
PROTEIN 3 PRECURSOR [lncyte PD: 1447003]
137. Fibronectin I line.vie PD:35537293
138. Earl5 growth response protein 1 {Incyte PD:1705208]
139. Human autoantigen DFS70 mRN A. partial cds {lncyte
PD:42920]
140. Prostaglandin-endoperoxide synffiase 2 (prostaglandin
G/H synthase and cyclooxygenase) {Incyte PD:3139163]
141. Synteni: YCFR 43 [YC 43.2000.W]
142. Synteni: YCFR 43 [YC 43.2000.Z]
143. Synteni: YCFR 23 [YC 23.0062.N]
144. Synteni: YCFR 43 [YC 43.2000.Y}
145. Homo sapiens phosphomevalonate kinase mRNA,
complete cds {Incyte PD: 1407123]
146. Synteni: YCFR 43 [YC 43.2000.X}
147. S.vnteni: YCFR 23 [YC 23.0031.N}
148. CARTILAGE GLYCOPROTEIN-39 PRECURSOR
[lncyte PD: 157510]
149. Synteni: YCFR 23 {YC 23.0125.N}
150. Synteni: YCFR 23 [YC 23.0250.N}
15 I. Synteni: YCFR 23 [YC 23.4000.N}
152. Human germline oligomenc matrix protein (COMP)
mRNA. complete cds {Incyte PD:2636634]
EXAMPLE 7
Prototype of the System
FIGS. 10 and 11 are partially dia_ammatic representa-
tions of one embodiment of the system 1. Spherical disks 2
of biocompatable material are arranged along the horizontal
spin filter or horizontal oxygenator of a standard rotating
wall perfused vessel or rotating wall batch-fed vessel 5.
The electrically conductive, bioattractive strips 6 are each
suitably embedded in or affixed to each of the disks such that
each disk has a positive and negative pole 12, associated
with positive and negative terminals 12 connected to respec-
tive endportions of the strips, as shown in FIG. IIA. As will
be more fully described, in one preferred embodiment in
which an alternating current is applied to the strips, the
polarity of the strips changes cyclically in correspondence
with the change in polarity of the applied current. Each
biocompatable disk is preferably two-sided, allowing
growth of tissue on both the lelt and right portions of the
spherical disk. Sterilization of the reactor core is effected by
one of multiple sterilization procedure, either ethylene oxide
sterilization, autoclave sterilization if the polymer permits,
or in the case of the batch-fed vessel, sterilization with
hydrogen peroxide. After sterilization and sufficient detoxi-
fication procedures, cellular material is seeded into the
reactor at a level to be determined according to the cell line
of interest.
A source of time varying current 10, suitably a laboratory
current source with adjustable wave-forn output connected
to a remote power source, not shown, is operable to provide
a time varying current, suitably of a value of about 1 mA to
20
about 1,000 mA, in the present embodiment. The time
varvin,,.=, current is suitably an alternating current, as indi-
cated above, although in other embodiments it is a pulsating
DC current. The current is conducted from the source 10
5 along first and second conductors 13A and 13B to slip rings
4. The slip rings are non-rotatable relative to the vessel 5,
and therelk_re rotate with the vessel during operation. Cur-
rent received through conductors 13A and 13B is conducted
through the associated slip rings to first and second sets of
to conductors, represented by first and second conductors 14A
and 14B, which are preferably insulated with an insulative
material, not shown, compatible with the fluids and products
within the bioreactor chamber. Each conductor is mechani-
call 3' connected to a respective peripheral portion of each of
15 the respective discs, and electricall3 connected with an end
portion of one of the conductive strips 6 (FIGS. 1A and IB ).
As viewed in FIG. 10, conductor 14A and the associated slip
ring are indicated to be of positive (+) polarity, and conduc-
tor 14 B and its associated slip ring are indicated to be of
20 relatively negative (-) polarity. As suggested above, upon
the current changing in polarity, conductor 14A will momen-
tarilx have a negative potential relative to conductor 14B,
therebx permitting a time varying current, which in this
embodiment is an alternating current, to flow through con-
25 ductor 6 which. In other embodiments, the time-var._ing
current ma_ be in the form of a pulsating DC current,
suitably a square wave or other waveform, rather than an
alternating current, in which case the conductors 14A and
14B and their associated slip rings remain of the same
_0 polarity but of differing potentials.
After inoculation, the rotating wall vessel 5 is rotated at
an appropriate speed and single cellular material begins to
attach onto the surface of the biocompatable material 6.
After initial growth of one 24- or 48-hour period, electrical
35 stimulation, i.e.. potentiation, begins via continuous low-
level or pulsatile electrical flow through each disk in series.
Discussion
Use of the methods of the present invention to control the
prolilerative rate of normal human adult astrocytes and
4o normal human neural progenitor cells (NHNP) has been
demonstrated. The procedure is applicable to, but not limited
to, the control of normal human neural cells in both two-
dimensional and threeimensional culture. As presented in
the molecular genetic data shown in Table 5 and Table 6,
45 many of the genetic responses in both up regulated and down
regulated genes are maturation and growth regulatory in
nature. An inspection reveals these genes are also primarily
involved in the eipbryogenic process. Therefore it is rea-
sonable to conclude that control over the embryogenic
5o development process can be achieved via the presently
demonstrated methodology.
As shown in Table 6, specific genes such as human
germline oligomeric matrix protein, prostaglandin endoper-
oxide synthase 2. earl 5' growth response protein 1, and
55 insulin like growth factor binding protein 3 precursor are
highly up regulated, while Keratin Type II cytoskelatal 7,
mytotic kinesin like protein 1. transcription factor 6 like 1,
mytotic feedback control protein, and cellular retinoic acid
binding protein are down regulated (Table 5 ). Each of these
6o two sets or classes of genes are on13 examples ffon3 the sum
of approximately 320 genes changes expressed as a conse-
quence of exposure to electrical potentiation.
As is clearly demonstrated in the human bod3, the
bioelectric, biochemical process of electrical nerxe stimula-
65 lion is a documented reality. The present invention demon-
strates that the same phenomena can be potentiated in a
synthetic atmosphere, i.e., in rotating wall cell cuhure yes-
US 6,485,963 B l
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sels. As may be understood from the forgoing discussion,
this electrical potentiation can be used for a number of
purposes.
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3. Goodwin. el al., In V;lm Cell De_: Biol.. 28A:47-60
( 19921.
4. Goodwin, et al., Proc. Soc. EV_. Biol. Med., 202:181-192
( Ic;93 !.
5. Goodwin, et al., J. Cell Biochem.. 51:301-311 ( 1093_.
6. Goodwin, et al., In 1'Ttro (ell Dev. Biol. Anita.,
33:366-374 ( 1997t.
7. Fukuda et al., U.S. Pat. No. 5,328,843
8, Aebischer, U.S. Pat. No. 5,030,225
An.',' patents or publications mentioned in this specifica-
tion are indicative of the levels of those skilled in the art to
which the invention pertains. These patents and publications
are herein incorporated by reference to the same extent as if
each individual publication was specifically and individually
indicated to be incorporated by reference.
One skilled in the art will readil', appreciate that the
present invention is well adapted to carry, out the objects and
obtain the ends and advantages mentioned, as well as those
inherent therein. The present examples along with the
methods, procedures, treatments, molecules, and specific
compounds described herein are presently representative of
preterred embodiments, are exemplary, and are not intended
as limitations on the scope of the invention. Changes therein
and other uses will occur to those skilled in the art which are
encompassed within the spirit of the invention as defined b 5
the scope of the claims.
What is claimed is:
1. A system for growing three-dimensional biological
cells, comprising:
a rotating wall vessel containing a cell-rich medium:
cell carriers placed within said vessel: and
an electrical current passed through said cell carriers for
producing an electromagnetic field within said cell-rich
medium.
2. The system of claim 1. wherein said cell carriers are
selected from the group consisting of spherical disks and
bioscaffold matrices containing multiple parallel channels.
3. The system of claim 2, wherein said channels are
coated with a bioattractive material.
4. The system of claim 3, wherein said channels, coated
with said bioattractive material, have longitudinal axes, and
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wherein said electrical current flows through said channels
along said longitudinal axes.
5. The system of claim 1. wherein said bioattractive
material is selected from the group consisting of titanium,
5 zirconium and platinunt.
6. The system of claim 1. wherein said biological cells
comprise mammalian cells selected from the group consist-
ing of neuronal cells, normal human neuronal progenitor
cells and cells responding to waveform.
J0 7. The system of claim 1, wherein said rotating wall vessel
is selected from the group consisting of a rotating wall
perfused vessel and a rotating wall batcfi-fed vessel.
8. The system of claim 1, wherein said electrical current
induces a cellular response at the gene level.15
9. The system of claim 8. wherein said cellular response
is cellular control of growth and differentiation at the gene
level.
10. Tile system of claim 1. wherein said electrical current
2o induces cellular control of growth and differentiation, for
suppressing or enhancing growth regulatory functions at
gene level.
11. The system of claim 1@ wherein said gene is associ-
ated with embryogenesis.
25 12. The system of claim 1. wherein said electrical current
is associated with a time varying potential.
13. The systent of claim 12. wherein said time varying
electrical potential is in the form of a square wave.
14. A method of culturing biological ceils in the system of
3o claim 1, comprising the steps of:
Inoculating said cells into said vessel:
rotating said vessel to initiate the attachment of said cells
to cell carriers:
35 applying an electrical potential to said cell carriers, and
measuring the growth of said cells.
15. The method of claim 14, wherein said vessel is rotated
at a speed of from about 10 RPM to about 30 RPM.
16. The method of claim 15, wherein said electrical
40
potential is associated with a current applied at a strength
range of from about 1 mA to about 6 mA.
17. The method of claim 14. wherein said electrical
potential is a time varying potential.
18. The metfiod of claim 17, wherein said time varying
45
potential is in a square wave.
